Dr. Lindsey's Multiple Sclerosis Website

Talk on new treatments--August 23, 2007

Active Clinical Trials at UT 2018
ACTRIMS Forum 2017
Tecfidera update September, 2016
AAN 2015
AAN 2014
Current Treatments (updated 7/7/13)
Gilenya (updated 4/20/2012)
Tysabri and PML
Recent and current research
Old meetings
New diagnosis of MS
Multiple Sclerosis Basic Information
Interferon versus Glatiramer--update 11/07
Talk on stem cells--2/13/08
About Dr. Lindsey
Research Interests
Clinic information
Contact Us
On August 23, 2007, I gave an informational talk for a group of patients.   
I talked about two topics.  The first topic was the various treatments in development for multiple sclerosis.  I just briefly discussed some of the many drugs which have finished the second phase of clinical testing which look promising.  Most of these are going into the last stage of clinical studies.  Several people asked if I could put the slides up on my website.  I haven't figured out how to put PowerPoint up here yet, but I have added the text from those slides below.  

I should emphasize that all of the treatments are still in the testing process.  None of them have been definitely shown to be useful for MS, although we hope that all of them will.  None of them are approved by the FDA for treatment of MS.  Most of them are not available outside of clinical studies. 

The second topic I talked about was my current work on whether Epstein-Barr virus causes MS.  Those slides are all graphs, so they are harder to put up on a website. 

Oral agent that affects the immune system
Phase II trial with 306 patients, 24 weeks
Relapse rate reduced 32%
MRI activity reduced 38%
Starting Phase III

Oral antibiotic which has anti-inflammatory properties and good CNS penetration
Phase II study with 40 subjects, GA+minocycline vs. GA alone, 9 months
Relapse rate reduced 42%
MRI activity reduced 65%

Affects circulation of lymphocytes, traps them in the lymph node
Phase II study, 281 patients, 6 months
Relapse rate reduced 55%
MRI activity reduced 80%*
Starting Phase III 

Monoclonal antibody specific for B cells
104 patients, 48 weeks
Relapse rate reduced 56%
MRI activity decreased 91%
Going to Phase III 

Monoclonal antibody against CD52 (found on many WBC)
334 patients, 2 years, compared to Rebif
Relapse rate reduced 75% *
Disability reduced 65%
3% ITP (one death), 15% Grave’s 

J. William Lindsey, MD
University of Texas Multiple Sclerosis Research Group
Houston, Texas

copyright 2007-2018 John William Lindsey